2025-14037Rule

DEA Slaps Another Year on Five Frankenstein Benzo Drugs

Published Date: 7/25/2025

Rule

Summary

The DEA is extending the temporary Schedule I status for five designer drugs—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—for one more year or until permanent rules are set. This means anyone making, selling, or using these drugs will keep facing strict legal controls and penalties. If you work with these substances, get ready to follow the same tough rules for now!

Analyzed Economic Effects

1 provisions identified: 0 benefits, 1 costs, 0 mixed.

One-Year Extension of Schedule I Controls

The DEA is extending the temporary Schedule I status of clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam for one year or until permanent rules are set. If you make, sell, import, export, research, teach about, chemically test, or possess these drugs, you will continue to be subject to the strict regulatory controls and administrative, civil, and criminal penalties that apply to Schedule I substances.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
7/25/2025

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in